Monashee Investment Management trims Structure Therapeutics stake by $12m

Monashee Investment Management has significantly reduced its exposure to Structure Therapeutics, cutting its position by 175,000 shares during the first quarter of 2026. The transaction, valued at approximately $11.98 million based on the quarter’s average closing price, was disclosed in an SEC filing dated May 13, 2026.

The reduction lowered Monashee’s total holding from roughly 225,000 shares to approximately 50,000 shares. The remaining stake now accounts for 1.8% of the firm’s 13F reportable assets. The total value of Monashee’s position in Structure Therapeutics decreased by $13.24 million over the quarter, a figure that reflects both the trading activity and the impact of stock price movements.

Structure Therapeutics is a clinical-stage biotechnology company developing oral therapies for chronic diseases, including type-2 diabetes and obesity. Its lead candidate, GSBR-1290, also known as aleniglipron, targets GLP-1 receptor agonism. The company is operating in a highly competitive weight loss drug market currently dominated by injectable medications such as Ozempic and Wegovy, although oral therapies are gaining traction due to potential advantages in manufacturing costs and patient preference.

Despite the institutional sell-down, Structure Therapeutics has seen strong share price performance. As of May 19, 2026, the company’s shares were priced at $35.88, representing a 42.55% increase from a year earlier. This performance outperformed the S&P 500 by 10.24 percentage points, even as Monashee opted to scale back its bet on the stock.

Monashee’s largest reported holding remains Medline Industries, valued at $13.35 million and comprising 7.3% of its assets under management. The decision to reduce, rather than fully exit, the Structure Therapeutics position may signal caution as the race for oral GLP-1 treatments intensifies among various pharmaceutical companies.